carboplatin + vindesine + temozolomide

This is a **combination chemotherapy regimen** consisting of three agents: **carboplatin**, **vindesine**, and **temozolomide**. All three are antineoplastic agents with distinct mechanisms of action, commonly used in various cancer chemotherapy protocols. **Carboplatin** is a platinum-based alkylating agent that causes DNA cross-linking and apoptosis. **Vindesine** is a vinca alkaloid that inhibits microtubule formation and therefore arrests cell division during metaphase. **Temozolomide** is an oral alkylating agent that methylates DNA, leading to tumor cell death. While combinations involving carboplatin, vincristine (another vinca alkaloid), and temozolomide have been studied, especially for pediatric low-grade gliomas, there is limited evidence or standard protocols specifically mentioning the combination of carboplatin, vindesine, and temozolomide as a common or named regimen in clinical practice[1][2][3][5]. The combination, if used, would be experimental or utilized in an off-label, investigational, or regionally specific context, and is presumed to leverage the synergistic cytotoxic effects of these three agents.